Share this page:
Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
Emergency use authorizations for two messenger RNA (mRNA) vaccines — the BNT162b2 vaccine (Pfizer–BioNTech) and the mRNA-1273 vaccine (Moderna) — marked important milestones in efforts to respond to the coronavirus disease 2019 (Covid-19) pandemic. These Food and Drug Administration actions were based on impressive results of clinical trials, but only in the weeks since the authorizations has real-world evidence been available to shed light on the overall effect of the vaccines on transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and related illness.
Date Last Updated (Year-Month-Day)
Daniel, William, Marc Nivet, John Warner, and Daniel K. Podolsky. 2021. "Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center." New England Journal of Medicine 384 (20):1962-3.
Free online on NEJM.